Table 1 The comparison of demographics and baseline characteristics in patients with different serum selenium levels.
From: Impact of selenium status and supplementation on outcomes in critically ill patients
Total sample n = 144 | Selenium level < 70 µg/L(n = 40) | Selenium level ≥ 70 µg/L (n = 104) | P value | |
|---|---|---|---|---|
Age | 68.6 ± 15.5 | 68.0 ± 15.6 | 68.9 ± 15.6 | 0.756 |
Age > 65 | 95(66%) | 26(65%) | 69(66.3%) | 0.879 |
Male | 91(63.2%) | 25(62.5%) | 66(63.5%) | 0.915 |
Comorbidity | ||||
Diabetes mellitus | 62(43.1%) | 17(42.5%) | 45(43.3%) | 0.933 |
Hypertension | 76(52.8%) | 25(62.5%) | 51(49%) | 0.147 |
Coronary artery disease | 29(20.1%) | 6(15%) | 23(22.1%) | 0.340 |
Chronic obstructive pulmonary disease | 17(11.8%) | 6(15%) | 11(10.6%) | 0.461 |
Stroke | 18(12.5%) | 2(5%) | 16(15.4%) | 0.157 |
Cirrhosis | 9(6.3%) | 2(5%) | 7(6.7%) | 1.000 |
Uremia | 15(10.4%) | 4(10%) | 11(10.6%) | 1.000 |
Autoimmune disease | 9(6.3%) | 1(2.5%) | 8(7.7%) | 0.445 |
Alcohol | 13(9%) | 3(7.5%) | 10(9.6%) | 1.000 |
Cancer | 46(31.9%) | 15(37.5%) | 31(29.8%) | 0.375 |
Comorbidity | 2.0 ± 1.5 | 2.0 ± 1.3 | 2.1 ± 1.6 | 0.934 |
Total comorbidity ≥ 2 | 87(60.4%) | 25(62.5%) | 62(59.6%) | 0.751 |
